Department of Medicine, Division of Global Public Health, School of Medicine, University of California San Diego, San Diego, CA, USA.
J Urban Health. 2010 Jul;87(4):576-85. doi: 10.1007/s11524-010-9463-3.
In January 2005, passage of California Senate Bill 1159 enabled California's county or city governments to establish disease prevention demonstration projects (DPDPs) through which pharmacies could subsequently register to legally sell up to 10 syringes to adults without a prescription. California's 61 local health jurisdictions (LHJs) were surveyed annually in 2005-2007 to monitor the progress of DPDP implementation and assess program coverage, facilitators, and barriers. Completed surveys were returned by mail, fax, e-mail, phone, or internet. We analyzed 2007 survey data to describe current DPDP status; data from all years were analyzed for trends in approval and implementation status. By 2007, 17 (27.9%) LHJs approved DPDPs, of which 14 (82.4%) had registered 532 (17.8%) of the 2,987 pharmacies in these 14 LHJs. Although only three LHJs added DPDPs since 2006, the number of registered pharmacies increased 102% from 263 previously reported. Among the LHJs without approved DPDPs in 2007, one (2.3%) was in the approval process, seven (16.3%) planned to seek approval, and 35 (81.4%) reported no plans to seek approval. Of 35 LHJs not planning to seek approval, the top four reasons were: limited health department time (40%) or interest (34%), pharmacy disinterest (31%), and law enforcement opposition (26%). Among eight LHJs pursuing approval, the main barriers were "time management" (13%), educating stakeholders (13%), and enlisting pharmacy participation (13%). The17 LHJs with DPDP represent 52% of California's residents; they included 62% of persons living with HIV and 59% of IDU-related HIV cases, suggesting that many LHJs with significant numbers of HIV cases have approved DPDPs. Outcome studies are needed to determine whether SB 1159 had the desired impact on increasing syringe access and reducing blood-borne viral infection risk among California IDUs.
2005 年 1 月,加州参议院法案 1159 的通过使加州各县或市政府能够建立疾病预防示范项目(DPDP),随后药剂师可以在该项目下注册,合法向成年人出售多达 10 支注射器,而无需处方。2005 年至 2007 年,每年对加州的 61 个地方卫生管辖区(LHJ)进行调查,以监测 DPDP 实施的进展情况并评估计划覆盖范围、促进因素和障碍。通过邮件、传真、电子邮件、电话或互联网返回已完成的调查。我们分析了 2007 年调查数据,以描述当前 DPDP 的现状;所有年份的数据均用于分析批准和实施状况的趋势。到 2007 年,有 17 个(27.9%)LHJ 批准了 DPDP,其中 14 个(82.4%)在这 14 个 LHJ 中注册了 532 家(17.8%)药房。尽管自 2006 年以来只有三个 LHJ 增加了 DPDP,但已注册的药房数量增加了 102%,从之前报告的 263 家增加到 532 家。在 2007 年没有批准 DPDP 的 LHJ 中,有 1 个(2.3%)处于批准过程中,有 7 个(16.3%)计划寻求批准,有 35 个(81.4%)表示没有计划寻求批准。在不打算寻求批准的 35 个 LHJ 中,排名前四位的原因是:卫生部门时间有限(40%)或兴趣有限(34%)、药房不感兴趣(31%)和执法部门反对(26%)。在寻求批准的 8 个 LHJ 中,主要障碍是“时间管理”(13%)、教育利益相关者(13%)和争取药房参与(13%)。有 DPDP 的 17 个 LHJ 代表了加州 52%的居民;其中包括 62%的艾滋病毒感染者和 59%的与 IDU 相关的艾滋病毒感染者,这表明有许多 HIV 病例较多的 LHJ 已经批准了 DPDP。需要进行结果研究,以确定 SB 1159 是否如预期的那样增加了注射器的可及性并降低了加州 IDU 中血源性病毒感染的风险。